ROIVANT SCIENCES LTD. (ROIV) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 283.60M USD | Liabilities, Current |
| Cash and equivalents | 1.25B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 2.59B USD | Marketable Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $283.60M | $1.25B | $2.59B | (m) | (m) | (m) |
| 2026-03-31 | (m) | $281.24M | $1.42B | $2.87B | (m) | (m) | (m) |
| 2025-12-31 | (m) | $151.96M | $1.48B | $3.05B | (m) | (m) | (m) |
| 2025-09-30 | (m) | $133.86M | $1.24B | $3.15B | (m) | (m) | (m) |
| 2025-06-30 | (m) | $113.87M | $1.24B | $3.26B | (m) | (m) | (m) |
| 2025-03-31 | (m) | $149.41M | $2.72B | $2.17B | (m) | (m) | (m) |
| 2024-12-31 | (m) | $141.48M | $1.99B | $3.16B | (m) | (m) | (m) |
| 2024-09-30 | (m) | $556.25M | $1.96B | $3.43B | (m) | (m) | (m) |
| 2024-06-30 | (m) | $215.04M | $5.68B | (m) | (m) | $34.00M | (m) |
| 2024-03-31 | (m) | $266.76M | $6.54B | (m) | (m) | $35.25M | (m) |
| 2023-12-31 | (m) | $244.90M | $6.67B | (m) | (m) | $5.24M | (m) |
| 2023-09-30 | (m) | $265.55M | $1.41B | (m) | (m) | $4.91M | (m) |
| 2023-06-30 | (m) | $245.00M | $1.43B | (m) | (m) | $4.22M | (m) |
| 2023-03-31 | (m) | $272.45M | $1.68B | (m) | (m) | $2.76M | (m) |
| 2022-12-31 | (m) | $244.25M | $1.53B | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $230.74M | $1.60B | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $328.92M | $1.94B | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $184.37M | $2.06B | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $160.71M | $2.21B | (m) | $8.92M | (m) | (m) |
| 2021-09-30 | (m) | $303.44M | $2.50B | (m) | $9.81M | (m) | (m) |
| 2021-06-30 | (m) | $209.16M | $2.00B | (m) | $3.42M | (m) | (m) |
| 2021-03-31 | (m) | $218.96M | $2.06B | (m) | $11.22M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |